Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 10;10(11):2888.
doi: 10.3390/biomedicines10112888.

Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not

Alessia Argirò  1 , Annamaria Del Franco  1 , Carlotta Mazzoni  1 , Marco Allinovi  1 , Alessia Tomberli  1 , Roberto Tarquini  2 , Carlo Di Mario  3 , Federico Perfetto  1 , Francesco Cappelli  1 , Mattia Zampieri  1
Affiliations
Review

Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not

Alessia Argirò et al. Biomedicines. .

Abstract

Cardiac amyloidosis (CA), caused by the deposition of insoluble amyloid fibrils, impairs different cardiac structures, altering not only left ventricle (LV) systo-diastolic function but also atrial function and the conduction system. The consequences of the involvement of the cardiac electrical system deserve more attention, as well as the study of the underlying molecular mechanisms. This is an issue of considerable interest, given the conflicting data on the effectiveness of conventional antiarrhythmic strategies. Therefore, this review aims at summarizing the arrhythmic burden related to CA and the available evidence on antiarrhythmic treatment in this population.

Keywords: arrhythmias; atrial fibrillation; cardiac amyloidosis; pacemaker implantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The electrical phenotype of cardiac amyloidosis is characterized by 3 possible scenarios: atrial fibrillation, conduction disease and ventricular arrhythmias.
See this image and copyright information in PMC

References

    1. González-López E., Gallego-Delgado M., Guzzo-Merello G., de Haro-Del Moral F.J., Cobo-Marcos M., Robles C., Bornstein B., Salas C., Lara-Pezzi E., Alonso-Pulpon L., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 2015;36:2585–2594. doi: 10.1093/eurheartj/ehv338. - DOI - PubMed
    1. Chacko L., Martone R., Bandera F., Lane T., Martinez-Naharro A., Boldrini M., Rezk T., Whelan C., Quarta C., Rowczenio D., et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur. Heart J. 2020;41:1439–1447. doi: 10.1093/eurheartj/ehz905. - DOI - PubMed
    1. Baggiano A., Boldrini M., Martinez-Naharro A., Kotecha T., Petrie A., Rezk T., Gritti M., Quarta C., Knight D.S., Wechalekar A.D., et al. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc. Imaging. 2020;13:69–80. doi: 10.1016/j.jcmg.2019.03.026. - DOI - PubMed
    1. Griffin J.M., Rosenblum H., Maurer M.S. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circ. Res. 2021;128:1554–1575. doi: 10.1161/CIRCRESAHA.121.318187. - DOI - PMC - PubMed
    1. Mints Y.Y., Doros G., Berk J.L., Connors L., Ruberg F.L. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: A systematic review and clinical experience. ESC Heart Fail. 2018;5:772–779. doi: 10.1002/ehf2.12308. - DOI - PMC - PubMed

LinkOut - more resources